Top
Summary
All studies
Mortality
Serious outcomes
Recovery
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
 
Analgesics⏵
Antiandrogens⏵
Antihistamines⏵
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Monoclonals⏵
Mpro inhibitors⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors⏵
TMPRSS2 inh.⏵
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
All efmarodocokin alfa studies
..
Feedback
Home
c19early.org COVID-19 treatment researchEfmarodocokin AlfaEfmarodocokin Alfa (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta
Home Adoption Other Treatments
@CovidAnalysis

Outcomes in COVID-19 efmarodocokin alfa studies

Home
@CovidAnalysis
All
Studies
Feedback
All studies   Mortality   Serious outcomes   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -15% 1 266 Improvement, Studies, Patients Relative Risk Mortality -15% 1 266 RCTs -15% 1 266 Late -15% 1 266 Efmarodocokin Alfa for COVID-19 c19early.org October 2025 Favorsefmarodocokin alfa Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -15% 1.15 [0.59-2.11] death 17/132 15/134 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.69 Late treatment -15% 1.15 [0.59-2.11] 17/132 15/134 15% higher risk All studies -15% 1.15 [0.59-2.11] 17/132 15/134 15% higher risk 1 efmarodocokin alfa COVID-19 study c19early.org October 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.69 Effect extraction pre-specified(most serious outcome) Favors efmarodocokin alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -15% 1.15 [0.59-2.11] 17/132 15/134 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.69 Late treatment -15% 1.15 [0.59-2.11] 17/132 15/134 15% higher risk All studies -15% 1.15 [0.59-2.11] 17/132 15/134 15% higher risk 1 efmarodocokin alfa COVID-19 mortality result c19early.org October 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.69 Favors efmarodocokin alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -15% 1.15 [0.59-2.11] death 17/132 15/134 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.69 Late treatment -15% 1.15 [0.59-2.11] 17/132 15/134 15% higher risk All studies -15% 1.15 [0.59-2.11] 17/132 15/134 15% higher risk 1 efmarodocokin alfa COVID-19 serious outcome c19early.org October 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.69 Effect extraction pre-specified(most serious outcome) Favors efmarodocokin alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) 13% 0.87 [0.65-1.16] no recov. 132 (n) 134 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.35 Late treatment 13% 0.87 [0.65-1.16] 132 (n) 134 (n) 13% lower risk All studies 13% 0.87 [0.65-1.16] 132 (n) 134 (n) 13% lower risk 1 efmarodocokin alfa COVID-19 recovery result c19early.org October 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.35 Favors efmarodocokin alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -15% 1.15 [0.59-2.11] death 17/132 15/134 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.69 Late treatment -15% 1.15 [0.59-2.11] 17/132 15/134 15% higher risk All studies -15% 1.15 [0.59-2.11] 17/132 15/134 15% higher risk 1 efmarodocokin alfa COVID-19 Randomized Controlled Trial c19early.org October 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.69 Effect extraction pre-specified(most serious outcome) Favors efmarodocokin alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -15% 1.15 [0.59-2.11] 17/132 15/134 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.69 Late treatment -15% 1.15 [0.59-2.11] 17/132 15/134 15% higher risk All studies -15% 1.15 [0.59-2.11] 17/132 15/134 15% higher risk 1 efmarodocokin alfa COVID-19 RCT mortality result c19early.org October 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.69 Favors efmarodocokin alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -15% 1.15 [0.59-2.11] death 17/132 15/134 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.69 Late treatment -15% 1.15 [0.59-2.11] 17/132 15/134 15% higher risk All studies -15% 1.15 [0.59-2.11] 17/132 15/134 15% higher risk 1 efmarodocokin alfa COVID-19 peer reviewed studies c19early.org October 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.69 Effect extraction pre-specified(most serious outcome) Favors efmarodocokin alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -15% 1.15 [0.59-2.11] death 17/132 15/134 Improvement, RR [CI] Treatment Control COVASTIL Waters (DB RCT) 13% 0.87 [0.65-1.16] no recov. 132 (n) 134 (n) Efmarodocokin alfa COVID-19 outcomes c19early.org October 2025 Favors efmarodocokin alfa Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0